Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine, Fukuoka, Japan.
Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan.
J Clin Exp Hematop. 2020 Dec 15;60(4):146-158. doi: 10.3960/jslrt.20036. Epub 2020 Nov 4.
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries and is characterized by the clonal expansion of mature CD5 B cells. There have been substantial advances in the field of CLL research in the last decade, including the identification of recurrent mutations, and clarification of clonal architectures, signaling molecules, and the multistep leukemogenic process, providing a comprehensive understanding of CLL pathogenesis. Furthermore, the development of therapeutic approaches, especially that of molecular target therapies against CLL, has markedly improved the standard of care for CLL. This review focuses on the recent insights made in CLL leukemogenesis and the development of novel therapeutic strategies.
慢性淋巴细胞白血病（CLL）是西方国家最常见的成人白血病，其特征是成熟 CD5 B 细胞的克隆性扩张。在过去的十年中，CLL 研究领域取得了重大进展，包括反复出现的突变的鉴定，以及克隆结构、信号分子和多步骤白血病发生过程的阐明，为 CLL 的发病机制提供了全面的认识。此外，治疗方法的发展，特别是针对 CLL 的分子靶向治疗方法的发展，显著改善了 CLL 的治疗标准。本综述重点介绍了 CLL 白血病发生和新型治疗策略的最新研究进展。
